Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

McMaster University

$15,000.00

Phage biomaterials as antimicrobial products

FY 2023-24

Summary
Bacteriophages, or phages for short, are viruses that exclusively infect bacteria in a highly targeted manner. This targeted killing action is in stark contrast to the indiscriminate sledgehammer like action of antibiotics and is a major advantage of phages over antibiotics and many other antimicrobials. Phages exhibit a range of characteristics that make them very attractive as antimicrobials, while simultaneously challenging decades of experience in development of antimicrobial compounds. Active antibacterial compounds, such as phage, rarely make it to the market in raw form and require a manufacturing framework that can process products in formats suitable for both clinical and non-therapeutic uses with well-characterized shelf-life and stability of the active compound, as well as reliable technology for quality control and characterization at different stages of manufacturing and end use. The phage market suffers from a paucity of such supporting technologies. There are three major bottlenecks for phage applications regardless of the end use scenario: stability, delivery, and accessibility. Addressing these challenges has been the major focus of my research team for the past 7+ years. The focus of this proposal is a technology that enables the high throughput fabrication of bioactive phage-built microgels that can be used for killing pathogenic bacteria. The stability of our microgels results in ease of transportation and storage, expanding the range of applications. This is a platform technology and therefore we envision it to be of interest to industry in therapeutics, prophylaxis, and environmental biocontrol. The global bacteriophage market is expected to grow at compound annual growth rate (CAGR) of 4.5% from 2020 to 2030, with food & beverages having the largest revenue share in the global bacteriophage market. We have identified the food industry to be first to market our technology. Uses may include addition to animal feed to control infection and treating surfaces and packaging throughout the supply chain to minimize contamination.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
586927-2023
Name nom
Hosseinidoust, Zeinab ZH
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
100
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Agriculture and primary food production
Area of application fr
Agriculture et produits alimentaires primaires
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Biomedical technology
Research subject en
Génie biomédical
Research subject fr
Technologie biomédicale
Application title
Phage biomaterials as antimicrobial products
Keyword
accessibility; Antimicrobial resistance; delivery; microgels; phage; sprays; stabilization
Application summary
Bacteriophages, or phages for short, are viruses that exclusively infect bacteria in a highly targeted manner. This targeted killing action is in stark contrast to the indiscriminate sledgehammer like action of antibiotics and is a major advantage of phages over antibiotics and many other antimicrobials. Phages exhibit a range of characteristics that make them very attractive as antimicrobials, while simultaneously challenging decades of experience in development of antimicrobial compounds. Active antibacterial compounds, such as phage, rarely make it to the market in raw form and require a manufacturing framework that can process products in formats suitable for both clinical and non-therapeutic uses with well-characterized shelf-life and stability of the active compound, as well as reliable technology for quality control and characterization at different stages of manufacturing and end use. The phage market suffers from a paucity of such supporting technologies. There are three major bottlenecks for phage applications regardless of the end use scenario: stability, delivery, and accessibility. Addressing these challenges has been the major focus of my research team for the past 7+ years. The focus of this proposal is a technology that enables the high throughput fabrication of bioactive phage-built microgels that can be used for killing pathogenic bacteria. The stability of our microgels results in ease of transportation and storage, expanding the range of applications. This is a platform technology and therefore we envision it to be of interest to industry in therapeutics, prophylaxis, and environmental biocontrol. The global bacteriophage market is expected to grow at compound annual growth rate (CAGR) of 4.5% from 2020 to 2030, with food & beverages having the largest revenue share in the global bacteriophage market. We have identified the food industry to be first to market our technology. Uses may include addition to animal feed to control infection and treating surfaces and packaging throughout the supply chain to minimize contamination.